
|Videos|August 26, 2021
Role of Second Generation FLT3 Inhibitors in AML
Expert examines the status of second-generation FLT3 inhibitors in newly diagnosed AML patients and the challenge with comparing clinical trial efficacy endpoints.
Advertisement
Episodes in this series

Advertisement
Related to this article

Vorasidenib analyses featured at SNO 2026 examine longer-term outcomes and seizure burden in IDH-mutant glioma, underscoring the importance of sustained monitoring during oral therapy.

Dexmedetomidine is approved, becoming the first at-home treatment for schizophrenia-associated agitation.

Pharmacists can help identify uncontrolled risk factors, review medications, and reinforce when patients should seek emergency care.

The anti-CD20 antibody is the first drug approved specifically for the disease, based on phase 3 MAJESTY data showing higher remission vs tacrolimus.

In an interview with Pharmacy Times, Thomas Hope, MD, explains how earlier consideration of peptide receptor radionuclide therapy in neuroendocrine tumors makes treatment scheduling and continuity of care essential opportunities for pharmacists.

From survodutide titration to oral PCSK9 adherence and HF care models, AHA 2026 experts pointed to pharmacists as key to putting new data into practice.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Structured Blood Glucose Testing: Why Timing Matters
2
AHA 2026: Pharmacists at the Center of Cardiometabolic Care
3
Navigating State Vaccine Regulations: Challenges for Community Pharmacies
4
FDA Reportedly Shelves Commissioner's National Priority Voucher Program
5


